September 1, 2014
WHITEHOUSE STATION, N.J. (AP) - Drugmaker Merck & Co. says third-quarter profit rose 2 percent as reduced spending on overhead offset lower sales caused by new generic competition for its top-selling drug, Singulair. The maker of diabetes pill Januvia narrowed its 2012 profit forecast, to a range of $2.08 to $2.24 per share, from its July forecast of $2.04 to $2.30.
Merck says net income was $1.73 billion, or 56 cents per share. That was up from $1.69 billion, or 55 cents per share, a year earlier. Excluding charges totaling $1.2 billion, net income was $2.93 billion, or 95 cents per share, 2 cents more than analysts expected. Revenue was $11.5 billion, down 4 percent. Analysts expected $11.57 billion. Sales of asthma and allergy pill Singulair dove 55 percent, to $602 million.
Copyright 2014 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Viewers with disabilities can get assistance accessing this station's FCC Public Inspection File by contacting the station with the information listed below. Questions or concerns relating to the accessibility of the FCC's online public file system should be directed to the FCC at 888-225-5322, 888-835-5322 (TTY), or firstname.lastname@example.org.